---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000095"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T04:41:56.843747+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ProMIS initiates Phase 1b PRECISE-AD trial of PMN310 in Alzheimer's disease

## Summary
- Phase 1b PRECISE-AD trial initiated; evaluating PMN310 in 100 patients with early Alzheimer's over 12 months.
- PMN310 selectively targets toxic amyloid-beta oligomers, avoiding plaque to reduce ARIA risk associated with existing therapies.
- Phase 1a data showed favorable safety/tolerability profile and drug concentrations in CSF supporting target engagement.
- Certain interim data from PRECISE-AD expected in first half of 2026.
- Trial will assess safety, tolerability, PK, biomarkers, and clinical efficacy measures.

## SEC filing metadata
- accession: 0001558370-25-000095
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837025000095/0001558370-25-000095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837025000095/pmn-20250110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000095
- JSON: https://secwatch.observer/filing/0001558370-25-000095.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000095.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.